Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
Crinetics Pharmaceuticals Insider Sold Shares Worth $1,485,000, According to a Recent SEC Filing
Jeff E. Knight, Chief Operating Officer, on July 15, 2024, sold 27,000 shares in Crinetics Pharmaceuticals (CRNX) for $1,485,000. Following the Form 4 filing with the SEC, Knight has control over a
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler analyst Yasmeen Rahimi maintains $Crinetics(CRNX.US)$ with a buy rating, and maintains the target price at $97.According to TipRanks data, the analyst has a success rate of 38.9% and a
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Elevance Health (ELV) and Johnson & Johnson (JNJ)
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?QuantumScape Corporation (NYSE:QS) stock jumped 64.34% after the company announced it entered into an
Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
Express News | Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Form 144 | Crinetics(CRNX.US) Officer Proposes to Sell 145.64K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 10, $Crinetics(CRNX.US)$ Officer Betz Stephen F. intends to sell 3,000 shares of its common stock on Jul 10, with a total market value of approximately $145.64K. Betz
Crinetics(CRNX.US) Officer Sells US$661.2K in Common Stock
$Crinetics(CRNX.US)$ Officer Hassard James sold 15,000 shares of common stock on Jul 5, 2024 at an average price of $44.08 for a total value of $661.2K.Source: Announcement What is statement of
Express News | Crinetics Pharmaceuticals Shares Are Trading Higher After JP Morgan Raised Its Price Target From $47 to $54
JPMorgan Raises Price Target on Crinetics Pharmaceuticals to $54 From $47, Maintains Overweight Rating
Crinetics Pharmaceuticals (CRNX) has an average buy rating and a price target range of $48 to $97, according to analysts polled by Capital IQ.Price: 46.93, Change: +1.56, Percent Change: +3.44
Crinetics Pharmaceuticals Is Maintained at Overweight by JP Morgan
Crinetics Pharmaceuticals Is Maintained at Overweight by JP
Crinetics Pharmaceuticals Price Target Raised to $54.00/Share From $47.00 by JP Morgan
Crinetics Pharmaceuticals Price Target Raised to $54.00/Share From $47.00 by JP
J.P. Morgan Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $54
J.P. Morgan analyst Jessica Fye maintains $Crinetics(CRNX.US)$ with a buy rating, and adjusts the target price from $47 to $54.According to TipRanks data, the analyst has a success rate of 54.0% and
Express News | Crinetics Pharmaceuticals Inc : JP Morgan Raises Target Price to $54 From $47
Crinetics(CRNX.US) Officer Sells US$645.01K in Common Stock
$Crinetics(CRNX.US)$ Officer Pizzuti Dana sold 14,375 shares of common stock on Jul 3, 2024 at an average price of $44.87 for a total value of $645.01K.Source: Announcement What is statement of change
Form 144 | Crinetics(CRNX.US) Officer Proposes to Sell 661.26K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 5, $Crinetics(CRNX.US)$ Officer JAMES HASSARD intends to sell 15,000 shares of its common stock on Jul 5, with a total market value of approximately $661.26K. JAMES HASSA
Form 144 | Crinetics(CRNX.US) Officer Proposes to Sell 644.98K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 3, $Crinetics(CRNX.US)$ Officer DANA J PIZZUTI intends to sell 14,375 shares of its common stock on Jul 3, with a total market value of approximately $644.98K. DANA J PIZ
Crinetics(CRNX.US) Officer Sells US$1.4 Million in Common Stock
$Crinetics(CRNX.US)$ Officer Wilson Marc sold 32,129 shares of common stock on Jun 28, 2024 at an average price of $43.61 for a total value of $1.4 million.Source: Announcement What is statement of ch
Crinetics Pharmaceuticals Price Target Maintained With a $97.00/Share by Piper Sandler
Crinetics Pharmaceuticals Price Target Maintained With a $97.00/Share by Piper Sandler